	C 2011 Dec 31	C 2012 Dec 31	2013 Dec 31	2014 Dec 31	2015 Dec 31	R 2016 Dec 31	2017 Dec 31	2018 Dec 31	2019 Dec 31	2020 Dec 31	2021 Dec 31	2022 Dec 31	R 2023 Dec 31	2024 Dec 31	2025 Dec 31	TTM Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	1,301	1,573	1,809	1,977	2,193	2,420	2,491	2,771	3,071	2,902	2,957	2,770	1,996	2,013	1,837	1,774
Cost of Operating Revenue	678	863	957	1,116	1,173	1,234	1,161	1,310	1,511	1,374	1,398	1,254	1,004	1,034	958	928
Gross Profit	623	710	852	862	1,020	1,186	1,331	1,460	1,559	1,528	1,559	1,516	992	979	879	846
Gross Margin	47.9	45.1	47.1	43.6	46.5	49.0	53.4	52.7	50.8	52.7	52.7	54.7	49.7	48.6	47.9	47.7
Total Operating Expenses	1,084	1,351	1,503	1,730	1,846	2,003	2,055	2,248	2,503	2,268	2,261	2,105	1,543	1,560	1,383	1,348
Operating Profit	217	222	306	247	347	416	436	523	567	634	696	666	453	454	454	426
Operating Margin	16.7	14.1	16.9	12.5	15.8	17.2	17.5	18.9	18.5	21.8	23.5	24.0	22.7	22.5	24.7	24.0
Financing Income/(Expense) - Net	36	28	39	46	49	61	78	86	92	76	62	57	44	14	14	-2
Profit before Taxes	284	262	363	306	397	480	515	610	600	677	1,258	864	529	431	445	417
Income Taxes	93	85	123	109	159	176	189	229	186	200	313	244	164	118	118	108
Profit after Tax	191	177	265	264	321	304	326	381	414	478	944	621	603	413	327	310
PAT Margin	14.7	11.2	14.7	13.3	14.7	12.6	13.1	13.7	13.5	16.5	31.9	22.4	30.2	20.5	17.8	17.5
EPS - Basic - ex Extraordinary Items	83.01	76.71	104.12	85.56	103.18	132.09	141.55	165.26	179.85	207.38	410.06	269.47	158.31	136.21	141.85	134.51
EPS - Diluted - ex Extraordinary Items	83.01	76.71	104.12	85.56	103.18	132.09	141.55	165.26	179.85	207.38	410.06	269.47	158.31	136.21	141.85	134.51
EBIT	217	222	306	247	347	416	436	523	567	634	696	666	453	454	454	426
EBITDA	249	313	399	345	460	535	539	625	667	716	763	708	490	490	491	462
EBITDA Margin	19.1	19.9	22.1	17.4	21.0	22.1	21.6	22.6	21.7	24.7	25.8	25.5	24.5	24.4	26.7	26.1

Balance Sheet

Abridged

Understanding Balance Sheet

Sanofi India Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2011 Dec 31	C 2012 Dec 31	R 2013 Dec 31	2014 Dec 31	R 2015 Dec 31	R 2016 Dec 31	R 2017 Dec 31	2018 Dec 31	2019 Dec 31	2020 Dec 31	2021 Dec 31	2022 Dec 31	2023 Dec 31	2024 Dec 31	2025 Dec 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	667	829	947	1,263	1,251	1,575	1,444	1,592	2,129	1,833	2,138	1,610	1,248	1,127	801
Long-Term Investments	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Property Plant & Equipment - Net	188	235	389	474	570	585	571	564	365	363	342	324	323	329	315
Total Non-Current Assets	836	803	931	965	1,161	966	1,334	1,392	1,115	1,085	923	461	467	485	454
Total Assets	1,503	1,631	1,878	2,228	2,411	2,541	2,778	2,984	3,244	2,919	3,061	2,072	1,715	1,612	1,255
Total Current Liabilities	357	387	469	656	495	502	602	624	703	687	750	741	651	719	491
Long Term Debt	-	-	-	-	-	-	-	-	-	18	18	15	14	14	14
Total Non-Current Liabilities	29	41	63	86	158	156	150	141	99	113	86	55	48	32	14
Total Liabilities	386	427	532	742	653	658	751	765	802	800	835	796	700	751	506
Total Shareholders' Equity	1,117	1,204	1,347	1,486	1,759	1,883	2,026	2,219	2,442	2,119	2,226	1,276	1,015	861	749
Total Equity	1,117	1,204	1,347	1,486	1,759	1,883	2,026	2,219	2,442	2,119	2,226	1,276	1,015	861	749
Total Liabilities & Equity	1,503	1,631	1,878	2,228	2,411	2,541	2,778	2,984	3,244	2,919	3,061	2,072	1,715	1,612	1,255

Cash Flow

Abridged

Understanding Cash Flow Statement

Sanofi India Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2011 Dec 31	C 2012 Dec 31	2013 Dec 31	2014 Dec 31	2015 Dec 31	R 2016 Dec 31	2017 Dec 31	2018 Dec 31	2019 Dec 31	2020 Dec 31	2021 Dec 31	2022 Dec 31	2023 Dec 31	2024 Dec 31	2025 Dec 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	240	300	332	278	367	382	423	480	541	625	552	502	625	374	379
Working Capital - Increase/(Decrease)	23	17	-27	36	-112	-1	80	-28	-38	62	68	-46	-349	-29	72
Net CF from Operating Activities	263	317	305	314	255	381	503	453	503	688	620	456	276	346	451
Capital Expenditures - Net	65	66	174	18	29	69	57	57	75	41	13	-13	10	36	25
Net CF from Investing Activities	-536	-34	-368	11	-6	-214	-147	-152	-25	198	568	592	-10	-36	-25
Dividends Paid - Cash - Total	147	88	105	121	147	150	157	164	152	804	841	1,573	868	385	442
Debt - LT & ST - Issuance/(Retirement) - Total	-	-	-	-	-	-	-	-	-	-5	-7	-8	-8	-6	-4
Net Cash Flow from Financing Activities	-147	-88	-105	-121	-147	-180	-188	-197	-183	-808	-847	-1,581	-877	-391	-447
Free Cash Flow to Equity	197	251	131	296	226	312	446	396	428	642	601	461	258	304	421
Free Operating CF net dividend	50	162	26	66	-50	162	289	230	276	-158	-244	-1,139	-626	-75	-17
Free Operating CF	197	251	131	187	97	312	446	394	428	646	597	434	242	309	425

Business Segment Analysis

FY End:

Dec 25

Sanofi India Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical Business (100.0%)₹ 25.70 Cr

Revenue / Sales

Pharmaceutical Business (100.0%)₹ 1,837.40 Cr

Assets

Pharmaceutical Business (100.0%)₹ 1,254.80 Cr

Operating Income

Pharmaceutical Business (100.0%)₹ 454.00 Cr

Regional Segment Analysis

FY End:

Dec 25

Sanofi India Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (86.7%)₹ 1,592.90 CrSingapore (12.6%)₹ 230.70 CrOthers (0.8%)₹ 13.80 Cr

Historical Segment Analysis

Track how Sanofi India Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Dec 31	2022 Dec 31	2023 Dec 31	2024 Dec 31	2025 Dec 31

Pharmaceutical Business	23	22	34	36	26

Frequently Asked Questions

What is the revenue of Sanofi India Ltd.?

The latest trailing twelve month revenue of Sanofi India Ltd. is ₹ 1,773.80 Cr, reflecting a 1-year growth of -12.98% and a 3-year CAGR of -14.11%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sanofi India Ltd.?

The latest trailing twelve month net profit (PAT) of Sanofi India Ltd. is ₹ 309.80 Cr, with a 3-year earnings CAGR of -18.52%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sanofi India Ltd.?

The trailing twelve month EBITDA of Sanofi India Ltd. is approximately ₹ 425.50 Cr (based on an operating margin of 23.99%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sanofi India Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sanofi India Ltd. is 134.51. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sanofi India Ltd.?

The debt-to-equity ratio of Sanofi India Ltd. stands at 0.02. The interest coverage ratio is 250.29x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sanofi India Ltd.?

The estimated book value per share of Sanofi India Ltd. is 325.30 (derived from a P/B ratio of 10.23 and market price of ₹ 3,328.40), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sanofi India Ltd.?

The trailing twelve month operating cash flow of Sanofi India Ltd. is ₹ 450.90 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sanofi India Ltd. report consolidated or standalone financials?

Sanofi India Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.